A bioética nas vacinas ARNM e ensaios clínicos contra o SARS-CoV-2
DOI:
https://doi.org/10.61243/calamo.15.124Palavras-chave:
Vacina, SARS-CoV-2, Covid-19, Pacientes, BioéticaResumo
O presente estudo tem como objetivo analisar os principais aspectos que se tomaram em consideração para o desenvolvimento da vacina contra o SARS-CoV-2 durante a crise sanitária por COVID-19. Com esta finalidade, se analisará sua incidência nos campos de interesse: a bioética e o direito. De igual forma, aludiremos a uma série de questões referentes aos ensaios clínicos e o respeito aos
princípios bioéticos. Se apresentam casos como as vacinas de ARNm y el uso de métodos alternativos de ensaios clínicos. Com relação à vacina se abordam questões como a aprovação, a obtenção de licenças, os entes reguladores, assim como a importância da ciência e do direito.
Referências
Abdelrahman, Z., Li, M. y Wang, X. 2020. “Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza a respiratory viruses”. Frontiers in immunology, 11, 2309.
Acevedo Pérez. 2002. "Aspectos éticos en la investigación científica". Ciencia y enfermería 8 (1): 15-18.
Aguiló Regla, Josep. 2009. "Dos concepciones de la ética judicial". Doxa. Cuadernos de Filosofía del Derecho, 32: 525-539. DOI: https://doi.org/10.14198/DOXA2009.32.21
Alba Bermúdez. 2016. "Derechos del paciente: especial referencia a la legislación ecuatoriana". Revista de
Derecho UNED 19: 493-510.
Amanat y Krammer. 2020. "SARS-CoV-2 Vaccines: Status Report". Immunity 52: 583-589.
Atzrodt, Maknojia, McCarthy, Oldfield, Po, Stepp y Clements. 2020. "A Guide to COVID‐19: a Global Pandemic Caused by the Novel Coronavirus SARSCoV‐2". The FEBS Journal. Acceso el 3 de mayo de 2021. https://febs.onlinelibrary.wiley.com/doi/epdf/10.1111/febs.15375
Barratt, A., Olsen, I., Nezvalova, K., Kåsine, T., Lund, F., Hoel, H. y Aukrust, P. 2021. "Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19: A Randomized Trial". Annals of Internal Medicine.
Bonsall, M., Huntingford, C. y Rawson, T. 2021. "Optimal Time to Return to Normality: Parallel Use of COVID-19 Vaccines and Circuit Breakers". MedRxiv.
Callaway. 2020. "Should Scientists Infect Healthy People With the Coronavirus to Test Vaccines?". Nature 580, n.° 7801: 17.
Chen, Strych, Hotez y Bottazzi. 2020. "The SARSCoV-2 Vaccine Pipeline: An Overview". Current Tropical Medicine Reports: 1-4.
Cox, Edmund, Kratz, Lockwood y Shankar. 2020. "Regulatory Affairs 101: Introduction to Expedited Regulatory Pathways". Clinical and Translational Science 13, n.° 3: 451-461.
Ebola ça Suffit Ring Vaccination Trial Consortium. 2015. "The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola". British Medical Journal, 351: 3740.
Eyal y Lipsitch. 2020. "Ethical Comparators in Coronavirus Vaccine Trials". Harvard Business School.
Eyal, Lipsitch y Smith. 2020. "Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure". The Journal of Infectious Diseases 221, n.° 11: 1752-1756.
FAO. 2020. "Considerations for Regulatory Oversight of Clinical Trials in the Covid-19 Pandemic". Acceso el 2 de mayo de 2021. https://iris.paho.org/handle/10665.2/52266
González Calisto, Patarroyo Durá y Carreño Bodensiek. 2017. "Principio de justiciar en el aula y responsabilidad moral del docente frente a los estilos de aprendizaje". Revista de investigación, Desarrollo e inovación, 7 (2): 241-253.
Gorbalenya, Baker, Baric, Groot, Drosten, Gulyaeva y Penzar. 2020. "Severe acute respiratory syndromerelated
coronavirus: The species and its viruses - A statement of the Coronavirus Study Group". BioRxiv. Acceso el 1 de abril de 2021. https://digital.csic.es/handle/10261/212994
Hendaus. 2020. "Remdesivir in the Treatment of Coronavirus Disease 2019 (COVID-19): A Simplified Summary". Journal of Biomolecular Structure and Dynamics: 1-10.
Hunt, Saenz y Littler. 2019. "The global forum on bioethics in research meeting, “ethics of alternative clinical trial designs and methods in low -and middle- income country research: emerging themes and outputs». Trials 20, n.° 701: 1-7.
Jamrozik y Selgelid. 2020. "COVID-19 Human Challenge Studies: Ethical Issues". The Lancet Infectious Diseases 1-6.
Jiang, H., Zhang, L., Li, J. y Zhu, F. 2021. "Next Steps for Efficacy Evaluation in Clinical Trials of COVID-19 Vaccines". Engineering 7(7): 903-907.
Johnson y Bailey. 2020. "Urgent Legal Lessons From a Very Fast Problem: COVID-19". Stanford Law Review Online, Forthcoming: 1-12. Acceso el 15 de abril de 2021. https://ssrn.com/abstract=3567412
Khuroo, Khuroo, Sofi y Khuroo. 2020. "COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!". India: Preprints-ResearchGate. DOI: https://doi.org/10.1016/j.jceh.2020.06.003
Landwirth. 1990. "Medical-legal Aspects of Immunization. Policy and Practices". Pediatric clinics of North America 37, n.° 3: 771-784.
Lyngbakken, M., Berdal, J., Eskesen, A., Kvale, D., Olsen, I., Rueegg, C. y Dalgard, O. 2020. "A Pragmatic Randomized Controlled Trial Reports Lack of Efficacy of Hydroxychloroquine on Coronavirus Disease 2019 Viral Kinetics. Nature communications, 11(1), 1-6. DOI: https://doi.org/10.1038/s41467-020-19056-6
Maciorowski, D., Idrissi, S., Gupta, Y., Medernach, B., Burns, M., Becker, D., Durvasula, R. y Kempaiah, P. 2020. “A review of the preclinical and clinical efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir treatments against COVID-19”. SLAS DISCOVERY: Advancing the Science of Drug Discovery, 25(10), 1108-1122. DOI: https://doi.org/10.1177/2472555220958385
Manheim, D., Więcek, W., Schmit, V., Morrison, J. y 1Day Sooner Research Team. 2021. “Exploring Risks of Human Challenge Trials For COVID‐19”. Risk Analysis, 41(5), 710-720. DOI: https://doi.org/10.1101/2020.11.19.20234658
Maschke y Gusmano. 2020. "Ethics and Evidence in the Search for a Vaccine and Treatments for Covid-19". Acceso el 2 de abril de 2021. https://www.thehastingscenter.org/ethics-and-evidencein-the-search-for-a-vaccine-and-treatments-forcovid-19/
National Institute of Allergy and Infectious Diseases. 2020. "Safety and Immunogenicity Study of 2019-
nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)". Acceso el 22 de abril de 2021. https://clinicaltrials.gov/ct2/show/NCT04283461
Nichol, A. 2020. "Potential Implications of Testing an Experimental mRNA-based Vaccine During an Emerging Infectious Disease Pandemic". The American Journal of Bioethics, 20(7), W2-W3. DOI: https://doi.org/10.1080/15265161.2020.1763696
Nuffield Bioethics. 2020. "Fair and Equitable Access to COVID-19 Treatments and Vaccines". Acceso el 30 de abril de 2021. https://www.nuffieldbioethics.org/assets/pdfs/Fair-and-equitable-access-to-COVID-19-treatments-and-vaccines.pdf
Olaya, García, Torres, Ferro y Torres. 2006. "Caracterización de proceso productivo, logístico y regulatorio de los medicamentos". Vitae, Vol. 13, Núm. 2: 69-82. https://www.researchgate.net/publication/220034939_CARACTERIZACION_DEL_PROCESO_PRODUCTIVO_LOGISTICO_Y_REGULATORIO_DE_LOS_MEDICAMENTOS
Organización Mundial de la Salud-OMS. 2020. "Q&A: Ethics and COVID-19: Resource Allocation and Priority Setting". Acceso el 2 de abril de 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/ethicsand-covid-19
Pacheco, de Souza, de Lima y Longo. 2020. "Panorama mundial de estudos com a hidroxicloroquina para o tratamento da COVID-19". Journal of Health & Biological Sciences 8, n.° 1: 1-4. DOI: https://doi.org/10.12662/2317-3076jhbs.v8i1.3288.p1-4.2020
Prompetchara, Ketloy y Palaga. 2020. "Immune Responses in COVID-19 and Potential Vaccines: Lessons Learned from SARS and MERS Epidemic". Asian Pac J Allergy Immunol 38, n.° 11: 1-9. DOI: https://doi.org/10.12932/ap-200220-0772
Rabaan, A., Al-Ahmed, S., Haque, S., Sah, R., Tiwari, R., Malik, Y. y Rodríguez, A. 2020. "SARS-CoV-2, SARS-CoV, and MERS-COV: a Comparative Overview". Infez Med, 28(2), 174-184. https://pubmed.ncbi.nlm.nih.gov/32275259/
Rawl, John. 1995. De la justicia. Fondo de Cultura Económica, México.
Sáenz, Luna, Salas, Canario, Chamorro, Palacios, Quiroz, Saidón y Villela. 2018. "La ética de los diseños y métodos alternativos de ensayos clínicos. Una reflexión sobre el Foro Global de Bioética en Investigación del 2017". Revista Panamericana de Salud Pública, 42: 38. DOI: https://doi.org/10.26633/RPSP.2018.38
Scavone, Brusco, Bertini, Sportiello, Rafaniello, Zoccoli, Berrino, Racagni, Rossi y Capuano. 2020. "Current Pharmacological Treatments for COVID‐19: What’s Next?". British Journal of Pharmacology, 177(21): 4813-4824. DOI: https://doi.org/10.1111/bph.15072
Stern, Ariel y Sarah Mehta. 2018. "Adaptive Platform Trials: The Clinical Trial of the Future?". Harvard Business
School. https://hbsp.harvard.edu/product/622012-PDF-ENG
Tietze, Vimalnath, Aristodemou y Molloy. 2020. "Crisis-Critical Intellectual Property: Findings from the COVID-19 Pandemic". Centre for Technology Management Working Paper Series 2: 1-19. Acceso el 10 de abril de 2021. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3569282
Wang, Kream y Stefano. 2020. "An evidence based perspective on mRNA-SARS-CoV-2 vaccine development". Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, 26. DOI: https://doi.org/10.12659/msm.924700
Xie y Chen. 2020. "Insight Into 2019 Novel Coronavirus - An Updated Intrim Review and Lessons From SARS-CoV and MERS-CoV". International Journal of Infectious Diseases, 94: 119-124. DOI: https://doi.org/10.1016/j.ijid.2020.03.071
Yánez. 2020. "Bioética animal como respuesta al cartesianismo distópico". Revista Bioética y Derecho 50: 425-438. DOI: https://doi.org/10.1344/rbd2020.50.31834
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los-as autores conservan sus derechos de autor-a y autorizan a la revista Cálamo, de manera ilimitada en el tiempo, para incluir su texto en el número correspondiente de la revista, exhibirlo y distribuirlo en sus soportes impreso y virtual, nacional e internacionalmente. La revista permite el autoarchivo tanto del pre-print, como del post-print y de la versión final.
Cálamo es una revista de acceso abierto. Opera bajo la licencia Creative Commons CC BY-ND 4.0: Licencia Creative Commons Atribución-SinDerivadas 4.0 Internacional
